OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th...
February 22 2018 - 4:02PM
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage
biopharmaceutical company focused on discovering and developing
novel anti-cancer therapeutics, today announced that the Company
will report fourth quarter and full year 2017 financial results and
operational highlights on Thursday, March 8th, 2018. OncoMed
management will host a conference call and webcast at 4:30 p.m.
Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (855) 420-0692 (domestic) and (484) 756-4194
(international) using the conference ID# 4997704. The webcast of
the conference call can be accessed live on the Investor Relations
section of the OncoMed website, http://www.oncomed.com, and
will be available for replay through June 30th, 2018.
An audio replay of the conference call can be accessed by
dialing (855) 859-2056 (domestic) or (404) 537-3406 (international)
utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals OncoMed
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on discovering and developing novel anti-cancer
therapeutics. OncoMed has internally discovered a broad pipeline of
investigational drugs intended to address the fundamental biology
driving cancer's growth, resistance, recurrence and metastasis.
Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83),
rosmantuzumab (anti-RSPO3, OMP131-R10) and anti-TIGIT (OMP-313M32)
are part of OncoMed's strategic alliance with Celgene Corporation.
OncoMed is independently developing GITRL-Fc (OMP-336B11), as well
as continuing to pursue new drug discovery research. For further
information about OncoMed Pharmaceuticals, please see
www.oncomed.com.
Investor Relations Contact:
Peter RahmerTrout Groupprahmer@troutgroup.com(646) 378-2973
Mike ZanoniTrout Groupmzanoni@troutgroup.com(646) 378-2924
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Apr 2023 to Apr 2024